![]() If one trial returns poor results, Kite Pharma has the resources and support to recover and go on. Under the umbrella of Gilead, Kite Pharma has room to fail – a must when reaching for a daring goal like curing cancer. ![]() Companies with more product candidates stand a better chance of surviving a single setback. Smaller biopharmas with limited pipelines can have their stock decimated by a Phase III failure. Either they don’t work as anticipated, or they cause unforeseen side effects when used with a diverse mix of patients. Unfortunately, no matter how effective a drug looks in early testing and Phase I or Phase II trials, there is no guarantee that it will survive the vigorous Phase III studies.Īll too often, when applied to a larger population, new treatments turn out to be ineffective. After all, what could go wrong when a company has reached late-stage clinical trials for a new therapy? ![]() Those who are new to biopharma investing often express surprise when this happens. It’s pretty common to hear of investors who lost big when a biopharma stock tanked. What Are The Risks Of Investing in Biopharma? The truth is, no matter how promising a company’s pipeline, biopharma investments come with big risks. In addition to Kite Pharma’s suite of cancer treatment candidates, Gilead has drugs in late-stage clinical trials for the treatment of HIV/AIDS, diseases of the liver, inflammation disorders, respiratory conditions, and ebola.Īll of this sounds encouraging, and investors considering the biopharma industry might wonder why anyone wouldn’t buy Gilead stock. While it isn’t possible to invest in Kite Pharma exclusively, buying stock in parent company Gilead exposes investors to even more potential revenue from revolutionary new therapies. Ultimately, this science shows promise for both blood cancers and solid tumor cancers. The product candidate pipeline is exciting, as it includes a selection of engineered cell therapies designed to express chimeric antigen receptors (CAR) or T-cell receptors (TCR), depending on the cancer’s characteristics. This method has been particularly successful in some types of blood cancer, and Kite Pharma scientists are hard at work on expanding applications. The cells are returned to the body primed to attack the cancer, where they work to reduce symptoms and improve quality of life in patients. This is done by removing patients’ immune cells, then making alterations in those cells so they can detect specific antigens related to the patients’ cancer. Instead, it is working on customized solutions for individual patients. Kite Pharma isn’t taking a one-size-fits-all approach to cancer treatment. Scientists and researchers have made great strides towards this objective throughout Kite Pharma’s 30 year history, leading the field in cancer immunotherapy. Its mission is bold: to cure cancer outright. Kite Pharma doesn’t bother with small, incremental improvements to existing therapies. The question is, does the larger company show the same promise as Kite Pharma? Is Gilead Science a buy? What Does Kite Pharma/Gilead Do? While it is not possible to purchase Kite shares directly, today’s investors can buy parent company GIlead Science. Investors know that any breakthrough in cancer treatment is sure to deliver substantial profits, and they are buying shares in companies that show the most promise. This was a win for early Kite Pharma investors, as the company’s 2014 IPO saw shares priced at just $17.00 each. In fact, its work impressed industry leader Gilead Science so much that Gilead acquired Kite Pharma in 2017 at a price of $180.00 per share. Kite Pharma, with its unrelenting focus on cancer treatment, is one such company. Some are actively pursuing an outright cure for cancer in all its forms. Biopharma companies are still hard at work on more effective treatments that come with fewer side effects. While the prognosis is better for many patients diagnosed with cancer, the battle isn’t over. The good news is that more and more patients are surviving, thanks to improved therapies that are customized to specific cancers and to individual patients’ genetic profiles. In the United States, there are 1,762,450 new cases of cancer diagnosed each year, and 606,880 people die from the disease. Kite Pharma Stock Forecast: For many patients, cancer is a death sentence.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |